SULT1A1 Antikörper (Antigen Affinität reinigt)

Sulfotransferases (SULTs) are Phase II drug-metabolizing enzymes that catalyze the addition of a sulfuryl moiety to both endogenous compounds, including steroids and neurotransmitters, and certain xenobiotics, including N-hydroxy-2-acetylaminoflourine and phenolic compounds, like alpha-naphthol. SULTs may be involved in the individual genetic disposition, species differences, and organotropisms for toxicological effects of chemicals. Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 (SULT1A1) belongs to the sulfotransferase 1 subfamily. Members of the SULT1 family have demonstrated the ability to sulfonate simple (small planar) phenols including estradiol, thyroid hormones, environmental xenobiotics and drugs. SULT1A1 mediates the metabolic activation of carcinogenic N-hydroxyarylamines to DNA binding products and could so participate as modulating factor of cancer risk. There has been an explosion in information on sulfotransferase polymorphisms and their functional consequences, including the influence of SULT1A1 genotype on susceptibility to colorectal and breast cancer. Furthermore, an Arg213His polymorphism in SULT1A1 has a strong influence on the level of enzyme protein and activity in platelets, which have been widely used for phenotyping. Statistically significant associations were observed between the SULT1A1 genotype (Arg213His) and age, obesity and certain neoplasias (mammary, pulmonary, esophageal and urothelial cancer).

1. Klaassen CD. et al., 1998, Chem Biol Interact. 109 (1-3): 299-313.
2. Glatt H. 2000, Chem Biol Interact. 129 (1-2): 141-70.
3. Lindsay J. et al., 2008, Curr Drug Metab. 9 (2): 99-105.
4. Coughtrie MW. 2002, Pharmacogenomics J. 2 (5): 297-308.
5. Glatt H. et al., 2004, Naunyn Schmiedebergs Arch Pharmacol. 369 (1): 55-68.